B Jilma

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. doi Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood
    Sabine Knappe
    Medical University of Vienna, Department of Clinical Pharmacology, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Thromb Haemost 109:450-7. 2013
  2. doi The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease
    Petra Jilma-Stohlawetz
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Guertel 18 20, 1090 Vienna, Austria
    Thromb Haemost 108:284-90. 2012
  3. pmc Surface cooling for induction of mild hypothermia in conscious healthy volunteers - a feasibility trial
    Christoph Testori
    Department of Emergency Medicine, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Crit Care 15:R248. 2011
  4. doi ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion
    Jolanta M Siller-Matula
    Department of Cardiology, Medical University of Vienna, Austria
    Arterioscler Thromb Vasc Biol 32:902-9. 2012
  5. doi Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis
    J M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    J Thromb Haemost 8:2624-41. 2010
  6. doi A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease
    Bernd Jilma
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Thromb Haemost 104:563-70. 2010
  7. ncbi Homozygosity in the single nucleotide polymorphism Ser128Arg in the E-selectin gene associated with recurrent venous thromboembolism
    Bernd Jilma
    Department of Clinical Pharmacology, and Clinical Institute for Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Arch Intern Med 166:1655-9. 2006
  8. ncbi High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men
    Bernd Jilma
    Department of Clinical Pharmacology TARGET, Medical University Vienna, Austria
    Thromb Haemost 94:797-801. 2005
  9. ncbi The single nucleotide polymorphism Ser128Arg in the E-selectin gene is associated with enhanced coagulation during human endotoxemia
    Bernd Jilma
    Department of Clinical Pharmacology, Clinical Institute for Medical and Chemical Laboratory Diagnostics, Medical University Vienna, Wahringer Gurtel 18 20, A 1090 Wien, Austria
    Blood 105:2380-3. 2005
  10. ncbi Endotoxin-induced activation of the coagulation cascade in humans: effect of acetylsalicylic acid and acetaminophen
    T Pernerstorfer
    Department of Clinical Pharmacology, University of Vienna, Austria
    Arterioscler Thromb Vasc Biol 19:2517-23. 1999

Detail Information

Publications134 found, 100 shown here

  1. doi Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood
    Sabine Knappe
    Medical University of Vienna, Department of Clinical Pharmacology, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Thromb Haemost 109:450-7. 2013
    ..Thus, inhibition of TFPI might be a promising novel treatment approach, especially in haemophilia patients with FVIII inhibitors...
  2. doi The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease
    Petra Jilma-Stohlawetz
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Guertel 18 20, 1090 Vienna, Austria
    Thromb Haemost 108:284-90. 2012
    ..In conclusion, ARC1779 markedly increases VWF/FVIII levels and most importantly improves or even corrects thrombocytopenia in VWD type 2B patients. This underscores the in vivo potency of ARC1779...
  3. pmc Surface cooling for induction of mild hypothermia in conscious healthy volunteers - a feasibility trial
    Christoph Testori
    Department of Emergency Medicine, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Crit Care 15:R248. 2011
    ..The aim of this study was to investigate the feasibility and safety of non-invasive surface cooling for induction and maintenance of mild hypothermia (32 to 34°C) in healthy, conscious volunteers...
  4. doi ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion
    Jolanta M Siller-Matula
    Department of Cardiology, Medical University of Vienna, Austria
    Arterioscler Thromb Vasc Biol 32:902-9. 2012
    ..We investigated the stability, pharmacokinetic, and pharmacodynamic profile of the 2(nd) generation anti-von Willeband factor aptamer ARC15105...
  5. doi Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis
    J M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    J Thromb Haemost 8:2624-41. 2010
    ....
  6. doi A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease
    Bernd Jilma
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Thromb Haemost 104:563-70. 2010
    ..ARC1779 prevented the rapid consumption of VWF multimers together with agglutinated platelets that occurred in response to desmopressin challenge in patients with VWD type 2B...
  7. ncbi Homozygosity in the single nucleotide polymorphism Ser128Arg in the E-selectin gene associated with recurrent venous thromboembolism
    Bernd Jilma
    Department of Clinical Pharmacology, and Clinical Institute for Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Arch Intern Med 166:1655-9. 2006
    ..As this SNP enhances tissue factor-triggered coagulation in humans during systemic inflammation, we hypothesized that it may also predispose for the development of recurrent venous thromboembolism (VTE)...
  8. ncbi High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men
    Bernd Jilma
    Department of Clinical Pharmacology TARGET, Medical University Vienna, Austria
    Thromb Haemost 94:797-801. 2005
    ....
  9. ncbi The single nucleotide polymorphism Ser128Arg in the E-selectin gene is associated with enhanced coagulation during human endotoxemia
    Bernd Jilma
    Department of Clinical Pharmacology, Clinical Institute for Medical and Chemical Laboratory Diagnostics, Medical University Vienna, Wahringer Gurtel 18 20, A 1090 Wien, Austria
    Blood 105:2380-3. 2005
    ..The S128R E-selectin genotype is associated with procoagulant effects in a human model of endotoxin-induced, TF-triggered coagulation. This could contribute to its linkage with various thrombotic cardiovascular disorders...
  10. ncbi Endotoxin-induced activation of the coagulation cascade in humans: effect of acetylsalicylic acid and acetaminophen
    T Pernerstorfer
    Department of Clinical Pharmacology, University of Vienna, Austria
    Arterioscler Thromb Vasc Biol 19:2517-23. 1999
    ....
  11. doi Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study
    J M Siller-Matula
    Department of Cardiology, Medical University of Vienna, Vienna, Austria
    J Thromb Haemost 10:529-42. 2012
    ..Prognostic values of genotyping and phenotyping for assessment of clopidogrel responsiveness have been shown in independent studies...
  12. ncbi Lepirudin blunts endotoxin-induced coagulation activation
    T Pernerstorfer
    Department of Clinical Pharmacology TARGET, Vienna General Hospital, Wien, Austria
    Blood 95:1729-34. 2000
    ..Results from this trial provide a rationale for a randomized clinical trial on the efficacy of lepirudin in DIC. (Blood. 2000;95:1729-1734)..
  13. ncbi Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin-induced coagulation
    J M Leitner
    Department of Clinical Pharmacology, Division of Haematology and Immunology, Medical University of Vienna, Vienna, Austria
    Clin Pharmacol Ther 81:858-66. 2007
    ..1-, 14.5, and 3.5-fold in the placebo group, respectively. BIBT986 did not influence inflammation, fibrinolysis, or platelet activation. Therefore, BIBT986 is a potent anticoagulant in the human endotoxemia model...
  14. ncbi Influence of the Duffy antigen on pharmacokinetics and pharmacodynamics of recombinant monocyte chemoattractant protein (MCP-1, CCL-2) in vivo
    F B Mayr
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Int J Immunopathol Pharmacol 22:615-25. 2009
    ..RhMCP-1 is a highly selective chemoattractant for monocytes in humans. The Duffy antigen only minimally alters the pharmacokinetics of rhMCP-1 for doses up to 2 microg/kg...
  15. ncbi Effects of anticoagulation on thrombopoietin release during endotoxemia
    P Jilma-Stohlawetz
    Department of Clinical Pharmacology, The Adhesion Research Group Elaborating Therapeutics, Vienna University School of Medicine, Austria
    J Lab Clin Med 137:64-9. 2001
    ..Of potential clinical interest is the observation that the direct thrombin inhibitor lepirudin, in contrast to heparins, mitigated LPS-induced platelet activation...
  16. doi Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay
    J M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, and 5th Medical Department, Kaiser Franz Josef Hospital, Vienna, Austria
    J Thromb Haemost 8:351-9. 2010
    ..As no direct comparison between the two methods has been made so far, we investigated which laboratory approach has a better predictive value for stent thrombosis...
  17. ncbi Evidence against an effect of endothelin-1 on blood coagulation, fibrinolysis, and endothelial cell integrity in healthy men
    S Kapiotis
    Department of Clinical Pharmacology, University of Vienna, Austria
    Arterioscler Thromb Vasc Biol 17:2861-7. 1997
    ..In contrast to previous reports from preclinical experiments, ET-1 does not appear to affect coagulation or fibrinolysis, nor does this peptide induce relevant endothelial cell perturbations in humans...
  18. ncbi Effects of hyperinsulinemia on plasma levels of circulating adhesion molecules
    B Jilma
    Department of Clinical Pharmacology TARGET, Vienna University Hospital School of Medicine, Wien, Austria
    J Clin Endocrinol Metab 85:1748-51. 2000
    ..Hyperinsulinemia has no adverse effect on circulating ICAM-1, vascular cell adhesion molecule-1, E-selectin, vWF, or sTM and therefore does not directly induce endothelial activation...
  19. ncbi Reparixin, a specific interleukin-8 inhibitor, has no effects on inflammation during endotoxemia
    J M Leitner
    Department of Clinical Pharmacology, Division of Immunohaematology, Medical University of Vienna, Austria
    Int J Immunopathol Pharmacol 20:25-36. 2007
    ..In conclusion, our study showed that reparixin was safe but had no impact on endotoxin induced inflammation. In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model...
  20. ncbi Effects of sodium nitroprusside on hemodialysis-induced platelet activation
    B Jilma
    Department of Clinical Pharmacology TARGET, Vienna University Hospital School of Medicine, Austria
    Kidney Int 55:686-91. 1999
    ..As nitric oxide (NO) is a potent inhibitor of platelet activation, we were interested in whether HD-induced platelet activation could be blunted by a NO donor...
  21. doi Racial differences in endotoxin-induced tissue factor-triggered coagulation
    F B Mayr
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    J Thromb Haemost 7:634-40. 2009
    ..Moreover, preclinical data suggest a link between the Duffy antigen (=DARC, Duffy antigen receptor of chemokines) and coagulation...
  22. ncbi Partial inhibition of nitric oxide synthase primes the stimulated pathway of vWF-secretion in man
    T Pernerstorfer
    Department for Clinical Pharmacology, Vienna University Medical School, Vienna, Austria
    Atherosclerosis 148:43-7. 2000
    ..This may in part explain the higher vWF levels in cardiovascular diseases associated with impaired endothelial NO generation...
  23. ncbi The effects of supra-normal protein C levels on markers of coagulation, fibrinolysis and inflammation in a human model of endotoxemia
    Alexander O Spiel
    Departments of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Thromb Haemost 94:1148-55. 2005
    ..Low grade endotoxemia itself induces significant protein C activation, which correlates with the TNF release...
  24. ncbi Effects of the pan-selectin antagonist bimosiamose (TBC1269) in experimental human endotoxemia
    Florian B Mayr
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Shock 29:475-82. 2008
    ..This indicates a minor influence of this selectin antagonist in this model. In addition, infusion of bimosiamose was safe and well tolerated in human endotoxemia...
  25. ncbi Effects of low dose endotoxemia on endothelial progenitor cells in humans
    F B Mayr
    Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Atherosclerosis 195:e202-6. 2007
    ..Levels of circulating EPCs have been investigated in different inflammatory disease states. However, data on circulating EPC levels and systemic inflammation remain scarce and contradictory...
  26. ncbi Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS
    I Fuchs
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    J Thromb Haemost 4:2547-52. 2006
    ..Platelet hyperfunction contributes to acute coronary syndromes (ACS). Thus, we hypothesized that platelet function under high shear stress predicts recurrent ACS during long-term follow-up of ACS patients...
  27. ncbi Effect of intradermal tumor necrosis factor-alpha-induced inflammation on coagulation factors in dermal vessel endothelium. An in vivo study of human skin biopsies
    W Speiser
    Department of Clinical Pharmacology, and Clinical Institute of Medical and Chemical Laboratory Diagnostics, University of Vienna, Austria
    Thromb Haemost 85:362-7. 2001
    ..This procoagulant shift in the haemostatic balance on the cell surface, caused by TNF-alpha-induced inflammation, is likely to contribute to thrombosis associated with tissue inflammation in humans...
  28. ncbi Effects of carbon monoxide inhalation during experimental endotoxemia in humans
    Florian B Mayr
    Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Am J Respir Crit Care Med 171:354-60. 2005
    ..These LPS-induced changes were not influenced by CO inhalation. Inhalation of 500 ppm CO for 1 hour had no antiinflammatory effects in a systemic inflammation model in humans, as 250 ppm for 1 hour did in rodents...
  29. ncbi The C-reactive protein (+)1444C/T alteration modulates the inflammation and coagulation response in human endotoxemia
    Claudia Marsik
    Departments of Clinical Pharmacology and Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna, Austria
    Clin Chem 52:1952-7. 2006
    ..We hypothesized that this alteration may also be associated with the degree of inflammatory response and coagulation activation in a well-standardized model of systemic inflammation...
  30. ncbi Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia
    Judith M Leitner
    Department of Clinical Pharmacology, Division of Immunohaematology, Medical University of Vienna, Austria
    Clin Pharmacol Ther 79:23-34. 2006
    ..Effects on leukocytes and inhibition of interleukin-6 release seem to represent specific pharmacodynamic properties of recombinant human antithrombin...
  31. ncbi Antiplatelet activity during coadministration of the selective serotonin reuptake inhibitor paroxetine and aspirin in male smokers: a randomized, placebo-controlled, double-blind trial
    Nicole Kotzailias
    Department of Clinical Pharmacology, Medical University Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    J Clin Pharmacol 46:468-75. 2006
    ..05 between periods). The combination of paroxetine and aspirin did not further inhibit platelet plug formation under high shear stress in male smokers...
  32. ncbi Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans
    Ursula Hollenstein
    Department of Clinical Pharmacology, Internal Medicine I, Division of Infectious Diseases, Clinical Institute of Medical and Chemical Laboratory Diagnostics, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Clin Pharmacol Ther 71:368-74. 2002
    ..To evaluate the applicability of a well-established model of tissue factor-dependent coagulation for defining anticoagulant potency, we investigated the effects of acenocoumarol in experimental human endotoxemia...
  33. ncbi Granulocyte colony-stimulating factor (G-CSF) downregulates its receptor (CD114) on neutrophils and induces gelatinase B release in humans
    B Jilma
    Department of Clinical Pharmacology TARGET, Vienna University School of Medicine, Austria
    Br J Haematol 111:314-20. 2000
    ....
  34. ncbi Massive pulmonary embolism leading to cardiac arrest is associated with consumptive coagulopathy presenting as disseminated intravascular coagulation
    J M Leitner
    Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria
    J Thromb Haemost 8:1477-82. 2010
    ..We hypothesized that a DIC-like condition is relevant in patients whose pulmonary embolism leads to cardiopulmonary arrest and cardiopulmonary resuscitation (CPR)...
  35. ncbi Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand Factor levels in healthy men
    T Pernerstorfer
    Department of Clinical Pharmacology-TARGET, Vienna University Hospital School of Medicine, , A-1090, Vienna, Austria
    Atherosclerosis 155:389-93. 2001
    ..Thus, UFH decreases cP-selectin levels, which may reflect decreased platelet activation in vivo. An increase in cP-selectin under UFH therapy should alert the clinician to look for platelet destruction...
  36. doi Sex differences in the association between albumin and all-cause and vascular mortality
    G Grimm
    Medical University of Vienna, 1090 Vienna, Austria
    Eur J Clin Invest 39:860-5. 2009
    ..This study evaluated the predictive value of low serum albumin for all-cause-mortality in a large Viennese patient cohort and investigated sex differences in the association between serum albumin and mortality...
  37. ncbi Role of von Willebrand factor in vascular disease
    P Paulinska
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Hamostaseologie 29:32-8. 2009
    ..This review focuses on the role of VWF in ACS, ischaemic stroke and peripheral arterial disease and the relevance of therapeutic interventions targeting VWF for ACS patients...
  38. ncbi Heparin lowers plasma levels of activated factor VII
    T Pernerstorfer
    Department of Clinical Pharmacology TARGET, University of Vienna, Austria
    Br J Haematol 105:1127-9. 1999
    ..e. total factor VII) as measured by FVII antigen nor FVII activity were affected by UFH. These results may improve our understanding of the regulation of FVIIa levels and heparin's mode of action...
  39. ncbi Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia
    Ulla Derhaschnig
    Department of Clinical Pharmacology, University of Vienna, Vienna, Austria
    Crit Care Med 32:1136-40. 2004
    ..Therefore, we wished to determine if an alphaIL-6 Ab (B-E8) may also attenuate lipopolysaccharide-induced activation of coagulation in humans...
  40. ncbi Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans
    Bernd Jilma
    Department of Clinical Pharmacology, Vienna University, Vienna, Austria
    Clin Pharmacol Ther 72:403-10. 2002
    ..This lethal animal model suggested that tissue factor also influences inflammatory cascades...
  41. ncbi Circadian variation of granulocyte colony stimulating factor levels in man
    B Jilma
    Department of Clinical Pharmacology, TARGET, University Hospital of Vienna, Austria
    Br J Haematol 106:368-70. 1999
    ..This pronounced diurnal rhythm of G-CSF levels may help understand the circadian changes in circulating stem cells, bone marrow DNA synthesis, or bone marrow toxicity induced by some chemotherapeutic agents...
  42. doi Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine
    E Tauber
    Intercell AG, Campus Vienna Biocenter 6, Medical University Vienna, Vienna, Austria
    J Infect Dis 198:493-9. 2008
    ..The aim of the present trial was to evaluate the safety and tolerability of IC51, Intercell's Vero cell-derived, purified, inactivated JE vaccine...
  43. ncbi The pharmacokinetics and pharmacodynamics of a new sustained-release leuprolide acetate depot compared to market references
    J M Leitner
    Department of Clinical Pharmacology, Division of Immunohematology, Medical University of Vienna, Austria
    Int J Clin Pharmacol Ther 46:407-14. 2008
    ..The aim of this study was to compare the efficacy of Lutrate 3.75 and 7.5 mg depot to marketed references Lucrin 3.75 mg and Procrin 7.5 mg depot...
  44. ncbi Plasma levels of activated factor VII decrease during the menstrual cycle
    S Kapiotis
    Department of Clinical Pharmacology TARGET, General Hospital Vienna, University of Vienna, Austria
    Thromb Haemost 80:588-91. 1998
    ..This may at least partially explain the marked gender differences found in FVIIa...
  45. ncbi The Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms influence the late inflammatory response in human endotoxemia
    Claudia Marsik
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Clin Chem 51:2178-80. 2005
  46. doi Simvastatin and rosuvastatin mobilize Endothelial Progenitor Cells but do not prevent their acute decrease during systemic inflammation
    Alexander O Spiel
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Thromb Res 123:108-13. 2008
    ..Numbers of circulating EPCs decrease in various inflammatory diseases. Thus, we hypothesized that short term statin pre-treatment may alter the acute change in EPC levels during systemic inflammation...
  47. ncbi The fibrinogen -148 C/T polymorphism influences inflammatory response in experimental endotoxemia in vivo
    Florian M Kovar
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Thromb Res 120:727-31. 2007
    ..We evaluated the role of a frequent promoter polymorphism in the beta chain of the fibrinogen gene (-148 C/T) in a human in vivo model of experimental endotoxemia...
  48. ncbi Platelet function in mitochondriopathy with stroke and stroke-like episodes
    Nicole Kotzailias
    Department of Clinical Pharmacology TARGET, Vienna University School of Medicine, Wahringer Gurtel 18 20, A 1090, Vienna, Austria
    Thromb Haemost 91:544-52. 2004
    ..Therefore other mechanisms seem to be etiologically involved in the pathogenesis of stroke in patients with mitochondriopathy...
  49. ncbi Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C
    M Homoncik
    Division of Gastroenterology and Hepatology, Department of Internal Medicine IV, Medical University, Vienna, Austria
    Aliment Pharmacol Ther 21:49-55. 2005
    ..A pegylated interferon-alpha-induced decrease in platelet counts may become a limiting factor for continuation of therapy...
  50. doi Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma
    M E Gorczyca
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    J Thromb Haemost 10:1581-90. 2012
    ..The aptamer BAX499 (formerly ARC19499) is designed to improve hemostasis by specifically inhibiting TFPI...
  51. doi The effect of plasma removal from apheresis platelet concentrates on platelet function
    P Jilma-Stohlawetz
    Clinical Department of Blood Group Serology and Transfusion Medicine, Medical University Vienna, Vienna, Austria
    Vox Sang 102:258-60. 2012
    ..Neither plasma removal method affected collagen-induced aggregation. Thus, platelet function did not deteriorate significantly by either method...
  52. ncbi Rapid down modulation of P-selectin glycoprotein ligand-1 (PSGL-1, CD162) by G-CSF in humans
    Bernd Jilma
    Department of Clinical Pharmacology The Adhesion Research Group Elaborating Therapeutics, Vienna University School of Medicine, Vienna, Austria
    Transfusion 42:328-33. 2002
    ..As WBC activation decreases PSGL-1 expression on WBCs in vitro, the effects of G-CSF on PSGL-1 expression were examined...
  53. ncbi Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin
    Rosemarie A Reiter
    Department of Clinical Pharmacology, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Blood 102:4594-9. 2003
    ..5 hours to 2 hours. In contrast, CEPI-CT remained above normal in the placebo group for more than 4 hours. In conclusion, DDAVP accelerates normalization of the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors (+l-aspirin)...
  54. ncbi Platelet function predicts myocardial damage in patients with acute myocardial infarction
    Martin Frossard
    Department of Clinical Pharmacology, Medical University, Vienna, Austria
    Circulation 110:1392-7. 2004
    ....
  55. ncbi Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans
    Rosemarie Reiter
    Department of Clinical Pharmacology, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Thromb Haemost 90:898-903. 2003
    ..001) at 6 h. In conclusion, PAR1 expression is down-regulated on platelets during systemic thrombin formation induced by inflammation in humans which results in decreased responsiveness to subsequent stimulation of the PAR1 receptor...
  56. doi Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation in human endotoxemia
    Ulla Derhaschnig
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Platelets 21:320-8. 2010
    ..NCX 4016, at the dose tested, unlike ASA, had no effect on platelet collagen/epinephrine induced plug formation under high shear rates...
  57. ncbi Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial
    Ulla Derhaschnig
    Department of Clinical Pharmacology, Vienna, Austria
    Am Heart J 147:E17. 2004
    ....
  58. ncbi Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy
    Ingrid Fuchs
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Crit Care Med 38:1423-9. 2010
    ..We tested the effect of an additional loading dose of 250 mg aspirin at the onset of acute coronary syndrome in patients who were already on chronic therapy with 100 mg aspirin...
  59. doi Hypertensive emergencies are associated with elevated markers of inflammation, coagulation, platelet activation and fibrinolysis
    U Derhaschnig
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    J Hum Hypertens 27:368-73. 2013
    ..Further studies will be needed to clarify if these alterations are cause or consequence of target organ damage...
  60. ncbi Polymorphism in the tissue factor region is associated with basal but not endotoxin-induced tissue factor-mRNA levels in leukocytes
    C Marsik
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    J Thromb Haemost 4:745-9. 2006
    ..We hypothesized that a frequent D/I polymorphism, at nucleotide position -1208 in the promoter region, could influence TF-mRNA and downstream coagulation...
  61. ncbi Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans
    A O Spiel
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    J Thromb Haemost 4:411-6. 2006
    ..Endotoxemia leads to systemic activation of the coagulation system and fibrinolysis in humans...
  62. doi A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura
    Petra Jilma-Stohlawetz
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Thromb Haemost 106:539-47. 2011
    ..However, the tested doses, particularly the daily s.c. injections, did not correct all clinical or laboratory features of TTP...
  63. doi Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura
    Petra Jilma-Stohlawetz
    Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria
    Thromb Haemost 105:545-52. 2011
    ..Based on its mechanism of action and the observed effect on platelet counts, ARC1779 used as an adjunctive to PEX may help accelerate recovery from organ dysfunction...
  64. doi Increased platelet aggregation and in vivo platelet activation after granulocyte colony-stimulating factor administration. A randomised controlled trial
    Alexander O Spiel
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Thromb Haemost 105:655-62. 2011
    ..G-CSF enhances platelet aggregation and activation in humans. This may put patients suffering from cardiovascular disease and cancer at risk for thrombotic events...
  65. ncbi Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia
    Ulla Derhaschnig
    Department of Clinical Pharmacology, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Blood 102:2093-8. 2003
    ..Infusion of rhAPC decreases "spontaneous" activation of coagulation but does not blunt LPS-induced, TF-mediated coagulation in healthy volunteers, which is in contrast to a number of anticoagulants...
  66. ncbi Angiotensin receptor blockade decreases markers of vascular inflammation
    Monika Graninger
    Department of Clinical Pharmacology, Vienna University, Vienna, Austria
    J Cardiovasc Pharmacol 44:335-9. 2004
    ..While such preventive effect will have to be proven in clinical trials, our results do not support a preference for either enalapril or losartan with regard to their possible vasoprotective role...
  67. ncbi Enalapril does not alter adhesion molecule levels in human endotoxemia
    Monika Graninger
    Department of Clinical Pharmacology and Division of Angiology, Vienna University, Vienna, Austria
    Shock 19:448-51. 2003
    ..Our results do not support the concept of a beneficial clinical effect of enalaprilat in septicemia...
  68. ncbi Altered platelet plug formation in hyperthyroidism and hypothyroidism
    Monika Homoncik
    Department of Internal Medicine IV, Medical University of Vienna, Austria
    J Clin Endocrinol Metab 92:3006-12. 2007
    ..Because vWF plays an important role in primary hemostasis, we hypothesized that heightened and decreased vWF levels in hyper- and hypothyroidism enhance and decrease platelet plug formation, respectively...
  69. ncbi Evidence of a U-shaped association between factor XII activity and overall survival
    G Endler
    Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna, Austria
    J Thromb Haemost 5:1143-8. 2007
    ..The current study evaluated the predictive value of FXII levels for all-cause mortality in a large Viennese patient cohort...
  70. ncbi Sex differences in HAART-associated dyslipidaemia
    H Pernerstorfer-Schoen
    Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases, University of Vienna Medical School, Vienna General Hospital, Vienna, Austria
    AIDS 15:725-34. 2001
    ..CONCLUSIONS: Metabolic adverse effects during HAART are more pronounced in women than in men. Hence, female HIV-infected patients seem to loose part of their natural protection from atherosclerosis during antiretroviral therapy...
  71. ncbi A new flow cytometric method for simultaneous measurement of residual platelets and RBCs in plasma: validation and application for QC
    P Jilma-Stohlawetz
    Department of Clinical Pharmacology, University of Vienna, Austria
    Transfusion 41:87-92. 2001
    ..Guidelines for the preparation of FFP in Austria and Germany require the quantification of residual RBCs in plasma. However, currently there is no validated method for enumeration of RBC counts as low as 1 x 10(9) per L...
  72. ncbi Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa
    E U Graefe-Mody
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    J Thromb Haemost 4:1502-9. 2006
    ..BIBT 986 is a novel potent anticoagulant with a dual mechanism of action: it competitively inhibits factor (F) Xa and FIIa...
  73. ncbi A proinflammatory state is detectable in obese children and is accompanied by functional and morphological vascular changes
    Stylianos Kapiotis
    Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna, Austria
    Arterioscler Thromb Vasc Biol 26:2541-6. 2006
    ..We hypothesized that inflammation in obese children is related to functional and early morphological vascular changes...
  74. doi In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model
    Wolfgang M Schmidt
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Pharmacogenet Genomics 18:109-20. 2008
    ..To gain insight into molecular mechanisms of anti-inflammatory effects of statins, we have studied global gene expression in circulating leucocytes in an in-vivo model of acute inflammation following statin administration...
  75. ncbi Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity
    Nadja Haiden
    Department of Pediatrics, Division of Neonatology and Intensive Care, University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Thromb Haemost 93:118-23. 2005
    ..Furthermore, Epo therapy is associated with an increase in the number of TO+ platelets compared to controls...
  76. ncbi Regulation of Fas (APO-1, CD95) and Fas ligand expression in leukocytes during systemic inflammation in humans
    Claudia Marsik
    Department of Clinical Pharmacology, Vienna University, Austria
    Shock 20:493-6. 2003
    ..The upregulation of Fas expression, Fas mRNA, and later in FasL and sFas levels in endotoxemia replicates the increased fas levels found in septic patients...
  77. doi Acute effects of hyperglycaemia on plasma concentration of soluble P-selectin and von Willebrand factor in healthy volunteers -a prospective randomised double blind controlled study
    Nicole Kotzailias
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Thromb Res 123:452-9. 2009
    ..6 and p<0.004 in all periods and p=0.2-0.9 between periods). In conclusion, acute hyperglycaemia for 6 hours does not increase the platelet and endothelial activation markers sP-selectin and VWF in healthy volunteers...
  78. ncbi Interspecies differences in coagulation profile
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Thromb Haemost 100:397-404. 2008
    ..Moreover, our findings confirm the potential usefulness of pigs as an experimental species to study fibrinolytic pathway and support the usefulness of rabbits as a species for examining platelets...
  79. ncbi Additive effects between platelet concentrates and desmopressin in antagonizing the platelet glycoprotein IIb/IIIa inhibitor eptifibatide
    Rosemarie Reiter
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Transfusion 45:420-6. 2005
    ..In case of bleeding, the drug can be stopped and PLT transfusions can be given...
  80. doi Platelet dysfunction in outpatients with left ventricular assist devices
    Barbara Steinlechner
    Division of Cardiothoracic and Vascular Anesthesia and Intensive Care, Medical University of Vienna, Vienna, Austria
    Ann Thorac Surg 87:131-7. 2009
    ..We therefore differentially evaluated platelet function with four commonly used point-of-care devices...
  81. doi In vivo profile of the human leukocyte microRNA response to endotoxemia
    Wolfgang M Schmidt
    Department of Clinical Pharmacology, Division of Pharmacogenetics and Imaging, Medical University of Vienna, A 1090 Vienna, Austria
    Biochem Biophys Res Commun 380:437-41. 2009
    ..The miRNAs and their potential target genes identified herein contribute to the understanding of the complex transcriptional program of innate immunity initiated by pathogens...
  82. doi In vitro platelet function of platelet concentrates prepared using three different apheresis devices determined by impedance and optical aggregometry
    Petra Jilma-Stohlawetz
    Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria
    Transfusion 49:1564-8. 2009
    ....
  83. doi Cross validation of aspirin effect in healthy individuals by Impact-R and PFA-100: a double blind randomized placebo controlled trial
    Ghazaleh Gouya
    Department of Clinical Pharmacology, Vienna, Austria
    Platelets 20:171-6. 2009
    ..There was, however, a significant level of absent concordance between the tests. Since the trial design cannot provide data on the specificity of the different tests, only clinical experience can determine their usefulness...
  84. ncbi Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria
    Thromb Haemost 102:397-403. 2009
    ..Maximal effects were seen 2 hours after aspirin loading and shorter than 72 hours after clopidogrel loading. In conclusion, aspirin and clopidogrel produce stronger signals in the MEA compared to several other methods...
  85. ncbi Point of care measurement of lepirudin and heparin anticoagulation during systemic inflammation
    Monika Homoncik
    Department of Clinical Pharmacology, Division of Immunology and Haematology, Vienna University School of Medicine, Wahringer Gurtel 18 20, A 1090 Wien, Austria
    Thromb Res 108:91-5. 2002
    ..As CoaguChek Plus (CCP) provides a rapid bedside test to monitor therapy with other anticoagulants, we aimed to determine its suitability for lepirudin therapy...
  86. ncbi Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemia
    Ulla Derhaschnig
    Department of Clinical Pharmacology, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Thromb Haemost 90:1054-60. 2003
    ..Additionally, the increase of TNF-alpha and IL-6 was similar in all groups. In conclusion, GPIIb/IIIa blockade with eptifibatide or tirofiban did not influence TF-induced coagulation activation in human low grade endotoxemia...
  87. ncbi Platelet function under high-shear conditions from platelet concentrates
    Petra Jilma-Stohlawetz
    Department of Blood Group Serology and Transfusion Medicine and Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Transfusion 48:129-35. 2008
    ..Platelet (PLT) collection and storage affect the functional capacity of PLTs in PLT concentrates (PCs). Therefore, PLTs' functional quality should be studied before transfusion...
  88. ncbi The tumor necrosis factor alpha -308 G/A polymorphism does not influence inflammation and coagulation response in human endotoxemia
    Florian M Kovar
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Shock 27:238-41. 2007
    ..Thus, if any, the impact of the TNF-alpha -308 G/A polymorphism on systemic endotoxin-triggered inflammation seems to be limited...
  89. ncbi The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma
    Ichiro Okamoto
    Department of Dermatology, Center of Excellence and the Ludwig Boltzmann Institute for Clinical and Experimental Oncology, Medical University of Vienna, Vienna, Austria
    J Invest Dermatol 126:2242-6. 2006
    ..Our data suggest that this polymorphism is a potential marker for disease severity that predicts earlier progression of MM...
  90. ncbi Effects of a combined therapy of erythropoietin, iron, folate, and vitamin B12 on the transfusion requirements of extremely low birth weight infants
    Nadja Haiden
    Department of Pediatrics, Division of Neonatology and Intensive Care, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Pediatrics 118:2004-13. 2006
    ..The aim of this trial was to investigate whether combined administration of vitamin B12, folic acid, iron, and erythropoietin could decrease transfusion requirements in extremely low birth weight infants...
  91. ncbi Immunomodulatory effects of fosfomycin in an endotoxin model in human blood
    Markus Zeitlinger
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna Vienna, Austria
    J Antimicrob Chemother 59:219-23. 2007
    ..This study set out to explore the immunomodulatory effects of fosfomycin, a broad-spectrum antibiotic frequently used in septic patients, at the protein and molecular levels in vitro...
  92. ncbi A randomized, controlled trial of the effects of adding vitamin B12 and folate to erythropoietin for the treatment of anemia of prematurity
    Nadja Haiden
    Department of Pediatrics, Division of Neonatology, Inborn Errors, and Pediatric Intensive Care, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Pediatrics 118:180-8. 2006
    ..We hypothesized that combined administration of vitamin B12 and folate with erythropoietin and iron would enhance erythropoietin-induced erythropoiesis...
  93. ncbi Coagulation interventions in experimental human endotoxemia
    Florian B Mayr
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Transl Res 148:263-71. 2006
    ..The aim of this review is to focus on coagulation interventions in the human endotoxemia model...
  94. ncbi Platelet glycoprotein Ibalpha polymorphisms and function evaluated by the platelet function analyzer PFA-100 in patients with lupus anticoagulant: the association with thromboembolic disease
    Petra Jilma-Stohlawetz
    Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Waehringer Guertel 18 20, 1090, Vienna, Austria
    Ann Hematol 86:719-25. 2007
    ..Thus, the Kozak dimorphism may just contribute to stronger factors disposing individuals with LA towards TE without any discernible effect on their in vitro platelet function estimated by the PFA-100...
  95. ncbi Activation of calcium-dependent calmodulin by calcium(II)3(3,5-diisopropylsalicylate)6(H2O)6 decreases thrombin receptor activating peptide-induced P-selectin expression
    Monika Homoncik
    Department of Clinical Pharmacology TARGET, Department of Internal Medicine IV, Division of Gastroenterology, Vienna University Hospital School of Medicine, Vienna, Austria
    Blood Coagul Fibrinolysis 14:131-8. 2003
    ..Improved calcium-dependent calmodulin activators may become useful drugs for the treatment of disorders associated with platelet activation, and P-selectin may decrease expression due to hemolysis...
  96. ncbi Marked increase in vascular endothelial growth factor concentrations during Escherichia coli endotoxin-induced acute inflammation in humans
    F Mittermayer
    Department of Clinical Pharmacology, University of Vienna, Vienna, Austria
    Eur J Clin Invest 33:758-61. 2003
    ..Bacterial endotoxins can induce the synthesis and release of vascular endothelial growth factor (VEGF), which may alter vascular permeability and cause vascular leakage...
  97. doi Troponin T predicts in-hospital and 1-year mortality in patients with pulmonary embolism
    K M Janata
    Dept of Emergency Medicine, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Eur Respir J 34:1357-63. 2009
    ..Elevated TNT independently predicts in-hospital and 1-yr mortality in patients with acute PE...
  98. ncbi Duffy antigen modifies the chemokine response in human endotoxemia
    Florian B Mayr
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Crit Care Med 36:159-65. 2008
    ..This trial was designed to investigate the influence of the Duffy antigen on human inflammation in vivo...
  99. pmc Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Br J Pharmacol 159:502-17. 2010
    ..Whether these potential advantages will translate into clinical advantages will require additional comparisons in properly powered, randomized, controlled trials...
  100. ncbi Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy
    Monika Homoncik
    Department of Internal Medicine IV, Division of Gastroenterology, Medical University Vienna, Vienna, Austria
    Am J Gastroenterol 101:2275-82. 2006
    ..Further, we hypothesize that EPO increases platelet reactivity and protease activated receptor 1 (PAR-1) expression during combination antiviral therapy...
  101. ncbi The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo
    Florian B Mayr
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Transfusion 50:1079-87. 2010
    ..The aptamer ARC1779 blocks binding of the VWF A1 domain to PLT glycoprotein Ib. We evaluated whether ARC1779 inhibits the excessive VWF activity and VWF-mediated PLT function in patients with TTP...